
HXNetRetatrutide
Ordered Retatrutide from HXNet? Mail in a sample (US only) and let us test it.
Test my supplyHXNet retatrutide shows a mixed purity-focus record: recent samples pass, but history includes a Feb identity failure and fill misses of +54%, +51%, +42%, +38%, and -37%. Weigh the post-June pass streak against that volatility.
Chinese registry snippets show the ChemicalBook anchor entity was cancelled before the current sales run. The report maps the HXTNT/LaraPharma channel shift, lookalike web infrastructure, and COA files that reuse third-party lab identifiers.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including HXNet rows.
Cancel anytime
Ordered Retatrutide from HXNet? Mail in a sample (US only) and let us test it.
Test my supplyAbout HXNet test results from Finnrick
HXNet is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 178 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible HXNet peptides in this dataset are Tirzepatide (52 tests), Semaglutide (5 tests) and BPC-157 (10 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 178 recent tests.
Ordered Retatrutide from HXNet? Mail in a sample (US only) and let us test it.
Test my supply